Proniras Corporation is a clinical-stage biotechnology company focused on the development of novel small-molecule therapeutics for the treatment of substance use and specialty central nervous system (CNS) disorders.

Development Programs

In the Press

Proniras Corporation Secures New Series B Financing and Names New Board Members to Support Phase 1 Study of Novel Treatment for Opiate Withdrawal

Proniras Corporation Announces National Institute on Drug Abuse (NIDA) Grant Award to Pursue Treatment for Opioid Withdrawal

Accelerator Life Science Partners Launches Proniras Corporation to Support Development of Tezampanel in the Treatment of Seizure Disorders